Factor V Leiden Heterozygous Mutation and Hyperhomocysteinemia Presenting with Vascular Rejection and Renal Allograft Infarction.

Suppr

超能文献

作者信息

Pahuja Taruna, Sangha Sukhwinder Singh, Sarkar Akash, Kanwar Yadav Raj

机构信息

Departmet of Nephrology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.

Departmet of Nephrology, Command Hospital, Cariappa Road, Lucknow Cantt, Lucknow, India.

出版信息

Indian J Nephrol. 2025 Jan-Feb;35(1):117-118. doi: 10.25259/IJN_330_2024. Epub 2024 Jun 12.

DOI:10.25259/IJN_330_2024

PMID:39872257

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11762829/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/852b/11762829/73772bab627d/IJN-35-1-117-g1.jpg

相似文献

Factor V Leiden Heterozygous Mutation and Hyperhomocysteinemia Presenting with Vascular Rejection and Renal Allograft Infarction.

Indian J Nephrol. 2025 Jan-Feb;35(1):117-118. doi: 10.25259/IJN_330_2024. Epub 2024 Jun 12.

Factor V Leiden mutation: potential thrombogenic role in renal vein, dialysis graft and transplant vascular thrombosis.

Curr Opin Nephrol Hypertens. 2001 May;10(3):409-14. doi: 10.1097/00041552-200105000-00018.

Hypercoagulable state in idiopathic ulcerative colitis: role of hyperhomocysteinemia and hyperfibrinogenemia.

Indian J Gastroenterol. 2008 May-Jun;27(3):94-8.

Arterial thrombosis associated with heterozygous factor V Leiden disorder, hyperhomocysteinemia, and peripheral arterial disease: importance of synergistic factors.

J Vasc Surg. 2005 Nov;42(5):1014-8. doi: 10.1016/j.jvs.2005.06.019.

Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.

Nephrol Dial Transplant. 1996 Apr;11(4):668-72. doi: 10.1093/oxfordjournals.ndt.a027357.

No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate-reductase gene.

Blood Coagul Fibrinolysis. 1999 Mar;10(2):101-5. doi: 10.1097/00001721-199903000-00007.

No interaction between factor V Leiden and hyperhomocysteinemia or MTHFR 677TT genotype in venous thrombosis. Results of a meta-analysis of published studies and a large case-only study.

Thromb Haemost. 2007 Jan;97(1):32-7.

Blood Coagul Fibrinolysis. 2020 Jan;31(1):55-59. doi: 10.1097/MBC.0000000000000878.

Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection.

Transplantation. 2000 Apr 27;69(8):1577-81. doi: 10.1097/00007890-200004270-00010.

Interrelation of hyperhomocysteinemia and inherited risk factors for venous thromboembolism. Results from the E.D.I.TH. study: a hospital-based case-control study.

Thromb Res. 2007;120(2):207-14. doi: 10.1016/j.thromres.2006.10.002. Epub 2006 Nov 28.

本文引用的文献

Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection.

Transplantation. 2000 Apr 27;69(8):1577-81. doi: 10.1097/00007890-200004270-00010.

High rate of acute rejections in renal allograft recipients with thrombophilic risk factors.

J Am Soc Nephrol. 1998 Jul;9(7):1309-13. doi: 10.1681/ASN.V971309.

The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients.

Transplantation. 1997 Aug 27;64(4):604-7. doi: 10.1097/00007890-199708270-00010.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验